Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Eledon Pharmaceuticals, Inc. | nvus-ex322_10.htm |
| EX-32.1 - EX-32.1 - Eledon Pharmaceuticals, Inc. | nvus-ex321_12.htm |
| EX-31.2 - EX-31.2 - Eledon Pharmaceuticals, Inc. | nvus-ex312_6.htm |
| EX-31.1 - EX-31.1 - Eledon Pharmaceuticals, Inc. | nvus-ex311_9.htm |
| EX-23.1 - EX-23.1 - Eledon Pharmaceuticals, Inc. | nvus-ex231_451.htm |
| EX-21.1 - EX-21.1 - Eledon Pharmaceuticals, Inc. | nvus-ex211_11.htm |
| EX-4.4 - EX-4.4 - Eledon Pharmaceuticals, Inc. | nvus-ex44_576.htm |
| 10-K - 10-K - Eledon Pharmaceuticals, Inc. | nvus-10k_20191231.htm |
|
|
|
Exhibit 23.2 |
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in Registration Statement Nos. 333-200413, 333-203032, 333-210058, 333-216432 and 333-232428 on Form S-8 and Registration Statement Nos. 333-218949 and 333-226286 on Form S-3 of our report dated March 16, 2020, relating to the consolidated financial statements of Novus Therapeutics, Inc., appearing in this Annual Report on Form 10-K of Novus Therapeutics, Inc. for the year ended December 31, 2019.
/s/ KMJ Corbin & Company LLP
Costa Mesa, California
March 16, 2020
|
|
|
|